Akihiro Bessho - Concepedia

Author

Akihiro Bessho

Okayama University ORCID

Also Known As

A Bessho, A. Bessho, AKIHIRO BESSHO, Akane Bessho, Akihiro BESSHO, Akihiro Bessho, Ayumu Bessho, Y Watanabe

212

Publications

Citations

H-Index

Concepts

All Affiliations

Okayama University Okayama Red Cross General Hospital Shikoku Cancer Center Okayama University Hospital Kyushu University

About

Akihiro Bessho is an author at Okayama University specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	27	1K
2	Health Sciences	6	6	255
3	Public Health	2	2	39
4	Biomedical Engineering	1	1	95
5	Blood Transplantation	1	1	10

Akihiro Bessho

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases Hideko Isozaki, Eiki Ichihara, Nagio Takigawa, Cancer Research OncologyMedicineReceptor Tyrosine KinaseAlectinib ResistancePharmacology	2016	128
Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001 Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, Journal of Thoracic Oncology First-line TherapyPhase Ii TrialMedicinePathologyBronchial Neoplasm	2015	103
The effects of a simplified method for cryopreservation and thawing procedures on peripheral blood stem cells Yoshio Katayama, Tomonori Yano, Akihiro Bessho, Bone Marrow Transplantation Simplified MethodThawing ProceduresMedicineStem Cell TransplantationHematology	1997	95
Interstitial Lung Disease in Japanese Patients With Non-Small Cell Lung Cancer Receiving Gefitinib Katsuyuki Hotta, Katsuyuki Kiura, Masahiro Tabata, The Cancer Journal	2005	75
Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, Journal of Thoracic Oncology MedicinePathologyBronchial NeoplasmGefitinib TreatmentCancer Treatment	2010	72
Detection of the T790M mutation of <i>EGFR</i> in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study) Takayuki Takahama, Kazuko Sakai, Masayuki Takeda, Oncotarget	2016	71
A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for <i>EGFR</i> -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Clinical Cancer Research	2021	70
Parathyroid hormone‐related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia Akio Hiraki, Hiroshi Ueoka, Akihiro Bessho, Cancer	2002	69
A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705 Hiroshige Yoshioka, Katsuyuki Hotta, Katsuyuki Kiura, Journal of Thoracic Oncology Pretreated PatientsPhase Ii TrialMedicineErlotinib MonotherapyPathology	2010	69
Advanced Age Is Not Correlated With Either Short-term or Long-term Postoperative Results in Lung Cancer Patients In Good Clinical Condition Shigeki Sawada, Eisaku Komori, Naoyuki Nogami, CHEST Journal Advanced AgeAdvanced Lung DiseaseMedicineBronchial NeoplasmThoracic Surgery	2005	63

Page 1